Full Length Research Paper

Relationship between adherence and health-related quality of life among HIV-patients in South Africa: findings and implications

Rajesh Vikram Vagiri¹, Johanna Catharina Meyer¹, Brian Godman¹,²,³,⁴ and Andries Gustav Stephanus Gous¹

¹School of Pharmacy, Sefako Makgatho Health Sciences University, Molotlegi Street, Pretoria, Republic of South Africa.
²Division of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden.
³Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
⁴Health Economics Centre, Liverpool University Management School, Liverpool, UK.

Received 27 October, 2018; Accepted 29 November, 2018

Greater access to highly active antiretroviral treatment (HAART) has increased the survival of people living with HIV and AIDS (PLWHA), and health-related quality of life (HRQoL) has emerged as an important indicator of treatment outcomes. However, the success of HAART depends on consistent and optimum adherence. Various cross-sectional studies and few longitudinal studies identified the relationship between HRQoL and HAART; however their association over time is still unclear. The objective of this study is to investigate the relationship between HRQoL and adherence to HAART over time. 431 PLWHAs were followed for one year at 4-monthly intervals. A descriptive adherence self-report rating scale and WHOQOL-HIV BREF were administered to collect adherence and HRQoL data respectively. Optimum adherence was set at ≥95%. Significant differences (p<0.05) in the overall mean HRQoL scores of the HAART adherent (≥95%) and non-adherent (<95%) patients were observed amongst patients on HAART for the periods of 9-28 months, 49-64 months and 81-120 months. This study established a strong relationship between adherence to HAART and HRQoL over time. Adherence to HAART is still a challenge and needs to be addressed through appropriate interventions.

Key words: Highly active antiretroviral therapy, health-related quality of life, medication adherence, interrupted time-series analysis, South Africa.

INTRODUCTION

HIV and AIDS has a devastating impact on morbidity and mortality across countries, with sub-Saharan Africa having the highest prevalence rates (WHO, 2014, 2018). Currently, 36.7 million people worldwide are living with HIV and AIDS, with 19.6 million people living in East and Southern Africa (Avert, 2017; US Department of Health

*Corresponding author. E-mail: rajesh.vagiri@gauteng.gov.za. Tel: (+27) 12 521 4567 Fax: (+27) 12 521 3992

Author(s) agree that this article remain permanently open access under the terms of the Creative Commons Attribution License 4.0 International License
Improved coverage and use of highly active antiretroviral treatment (HAART) has reduced morbidity and mortality in both children and adults with HIV and AIDS, with integrated approaches used to improve care and outcomes (Venter et al., 2017; Burrage et al., 2018). Improved care and an appreciable increase in access to HAART for people living with HIV and AIDS (PLWHA) have resulted in a 48% reduction in AIDS-related deaths since 2003, with the epidemic now declining (UNAIDS, 2017). Approximately 17 million PLWHA had access to HAART by end of 2015, and the global coverage of HAART has reached 46% (UNAIDS, 2016). South Africa has a high burden of infectious diseases (Statistics South Africa, 2018), with an estimated 7.52 million PLWHA (Statistics South Africa, 2018). Wider access to HAART through public health programs has resulted in life expectancy increasing from 54.9 years in 2002 to 64.2 years in 2018 among people with HIV in South Africa, which is encouraging (Statistics South Africa, 2018).

The evident effectiveness of HAART has resulted in an appreciable change in the patterns of mortality from HIV in South Africa, leading to increasing prevalence of HIV from 10.9% in 2002 to 12.6% in 2017 (Statistics South Africa, 2016). The increased life expectancy denoted by an ageing HIV-infected population is also impacting on the rate of non-communicable diseases (NCDs) in South Africa and other African countries, with increasing rates of patients with both HIV and NCDs (Meyer et al., 2017; Rwegerera et al., 2017). Several studies identified that PLWHA may have a higher prevalence and early age of onset of NCDs compared to the general population (Guaraldi et al., 2011; Althoff et al., 2014; Schouten et al., 2014). Treatment of NCDs poses challenges such as an increased pill burden impacting on adherence, increasing side-effects due to drug-drug interactions, as well as loss of treatment efficacy and subsequent virological breakthrough in patients with concomitant HIV, all of which may complicate HIV treatment (Deeks and Phillips, 2009; Althoff et al., 2016). With identified complexities relating to HAART and NCDs in PLWHA, coupled with reduced mortality, the focus over the last number of years has shifted to improving the health-related quality of life (HRQoL) of PLWHA (Oguntibeju, 2012; Van Tam et al., 2012; Balderson et al., 2013; Moorhouse, 2014; Owuor et al., 2014; Pasquau et al., 2018) as a key outcome measure.

Health-related quality of life (HRQoL) is one of the most used subjective aspects in assessing the impact of chronic disease conditions such as HIV, and is used as a key outcome variable for validating or reviewing current treatment approaches, assessing their effectiveness as well as in the approval of new therapeutic regimens (Geocze et al., 2010; Oguntibeju, 2012; Balderson et al., 2013; Smit et al., 2015; Etenyi et al., 2018). Strict or near perfect adherence to HAART (≥95%) is also a key determinant in optimal therapeutic outcomes of HAART, with non-adherence to HAART likely to lead to therapeutic failure, immune system deterioration, emergence of resistant strains and sub-optimal drug levels in the blood (Lyimo et al., 2012; Mghamba et al., 2013). This is a concern given still high prevalence rates for HIV and AIDS in sub-Saharan Africa, including South Africa. Published studies have also suggested that HAART potentially improves the HRQoL of patients, contributing to better adherence to HAART (Oguntibeju, 2012). Improved adherence will result in a greater suppression of the viral load and increased HRQoL (Campos et al., 2009). Although PLWHA experience the benefits of long-term use of HAART, various socio-demographic, clinical, psychological and behavioural determinants may negatively impact on their HRQoL (Degroote et al., 2014). On the other hand, greater adherence may lead to increased toxicities, resulting in decreased HRQoL (Mannheimer et al., 2008; Ncama et al., 2008; Airoldi et al., 2010). Tenofovir disoproxil fumarate (TDF) containing regimens for instance are associated with both liver and kidney toxicities and efavirenz has been associated with neuropsychiatric side-effects (Gaida et al., 2016; Kalemeera et al., 2016; Kalemeera et al., 2017; Mataranyika et al., 2017).

Although the initiative to improve the care of patients in the public health system in South Africa through the introduction of National Health Insurance (NHI) (Meyer et al., 2017) has increased HAART coverage; there are still concerns about the provision of clinical care, including issues of adherence to medicines for patients with chronic diseases affecting their HRQoL with or without HIV (Meyer et al., 2017; Rampamba et al., 2017).

It is known that a person’s HRQoL is influenced by several determinants, and these determinants individually or simultaneously influence perceived HRQoL over time (Degroote et al., 2014). We are also aware that the relationship between HRQoL and HAART has been identified in high income countries. However, the relationship between HRQoL and long-term adherence to HAART is still unclear, especially in sub-Saharan African countries where the HIV population is very different to Western countries with a greater predominance of women (Gaida et al., 2016; Kalemeera et al., 2016). Furthermore, in these countries there is a high predominance of NCDs with high rates of obesity and hypertension (Cois and Day, 2015; Meyer et al., 2017; Rampamba et al., 2017), and resources are constrained. Consequently, we sought to investigate the relationship between aspects of HRQoL and adherence to HAART over time in South Africa to provide future guidance.

It is known that whilst a number of cross-sectional studies and longitudinal studies from various settings...
have indicated a correlation between HRQoL and adherence to HAART (Mannheimer et al., 2005; Burgoyne and Tan, 2008; Ncama et al., 2008; Airoldi et al., 2010; Bello SI and Bello IK, 2013; Cohen et al., 2013; Silva et al., 2014; Vagiri et al., 2014), they have typically failed to establish a relationship over time due to the use of non-randomized convenience samples, insufficient sample size and use of HRQoL instruments not specific to PLWHA. They also failed to portray the HRQoL of patients according to the actual period of time they have been on HAART. We sought to address these deficiencies. Most HRQoL studies conducted globally using the WHOQOL-HIV BREF in PLWHA have also been cross-sectional in nature and predominantly focused on the perceptions about HRQoL or a specific HRQoL domain and adherence to HAART (Belak Kovačević et al., 2006; Peltzer and Phaswana-Mafuya, 2008; Fatiregun et al., 2009; Rüütel et al., 2009; Saddki et al., 2009; Hsiung et al., 2011; Imam et al., 2011; Tran, 2012; Bakiono et al., 2014; Vagiri et al., 2014; Tesfay et al., 2015; Surur et al., 2017).

Our study is different as it identified changes in HRQoL over time, and sought to ascertain if there was a relationship between HRQoL and adherence behaviour over time on HAART. Regular and repeated assessment of HRQoL can be used to track changes in functional status over time, especially in chronic illnesses like HIV, as well as to evaluate and monitor treatment effects (Grossman et al., 2003). Although ART can result in better clinical outcomes and potentially improved HRQoL, side effects of ART and change in adherence behaviour can negatively influence HRQoL (Oguntibeju, 2012).

Consequently, to our best knowledge, we believe this is the first longitudinal study to study the relationship between HRQoL and adherence to HAART considering the exact period of time the patient has been on HAART. In view of this, we believe our findings may be of interest not only to key stakeholders in South Africa but also to other sub-Saharan African countries with a high burden of HIV, greater predominance of women with HIV, and struggling to attain or retain universal access to healthcare, given increasing rates of NCDs.

**MATERIALS AND METHODS**

**Study design and sample**

This is a quantitative, longitudinal, cohort study conducted at Tshepang ARV Clinic at Dr George Mukhari Academic Hospital and the Tshwaragangang ARV Clinic at Phedisong 4 Community Health Centre between October 2013 and February 2015. Both study sites are in public sector settings situated north of Pretoria, are typical of such facilities throughout South Africa, and provide HAART for PLWHA.

A total of 563 patients (±18 years) were sampled randomly from the register of patients scheduled for appointments at each of the two study sites on a daily basis and were enrolled within the following strata: i) newly-initiated on HAART; ii) 1 to 12 months on HAART; iii) 12 to 36 months on HAART; and iv) >36 months on HAART.

nQuery Advisor® 6 software was used for the calculation of sample size. Sample size estimates were based on the following assumptions: i) 80% of subjects will report high levels of adherence and 20% will report lower levels of adherence; ii) a two-group t-test with a 0.05 two-sided significance level will have 80% power to detect a difference in means of 6.0 in the HRQoL score between patients with high levels of adherence and those with lower levels of adherence will be clinically meaningful; and iii) an expected drop-out rate of 30%, based on experience from a previous studies conducted at study sites (Kadam and Bhalerao, 2010; Noordzji et al., 2010). Recruited patients were followed-up at 4-monthly intervals for a period of 12 months. At the end of the study period, 431 patients remained in the study and attended all study visits.

**Data collection and instruments**

Data were collected by four well trained data collectors, two at each clinic, while patients awaited consultation with heath care professionals. Most HRQoL questionnaires specific to HIV and AIDS are long forms with an in-depth analysis of well-being, resulting in PLWHA being burdened with a long and time-consuming QoL assessment. The WHOQOL-HIV BREF was identified as the most suitable HRQoL questionnaire for this study due to its HIV and AIDS specificity, provides a snapshot of HRQoL, has the ability to distinguish between different stages of HIV disease progression, has good psychometric properties and has discriminant validity (Meemon et al., 2016; Tesfaye et al., 2016). The completion and administration process of the questionnaire is simple, providing a quick measure of HRQoL; consequently, making it ideal for administration to PLWHA in busy clinics (O’Connell and Skevington, 2012). In addition, the WHOQOL-HIV BREF had already been translated into different languages and validated in different study and cultural settings across multiple countries (Belak et al., 2006; Peltzer and Phaswana-Mafuya, 2008; Fatiregun et al., 2009; Rüütel et al., 2009; Saddki et al., 2009; Hsiung et al., 2011; Imam et al., 2011; Tran, 2012; Bakiono et al., 2014; Vagiri et al., 2014; Tesfay et al., 2015; Surur et al., 2017).

The WHOQOL-HIV BREF is a multi-dimensional instrument comprising 31-items covering six domains; namely, physical, psychological, level of independence, social relationships, environment, and spirituality/religion/personal beliefs. The WHOQOL-HIV BREF is based on the shorter WHOQOL-BREF which is an abbreviated version of the WHOQOL-100. Each domain has a set of facets and denotes a description of a behaviour, a state of being, a capacity or potential, or a subjective perception or experience (O’Connell and Skevington, 2012). Individual items on the WHOQOL-HIV BREF were rated on a five-point Likert scale, ranging from one (low or negative perception) to five (high or positive perception).

Socio-demographic data, health-related characteristics and adherence data were obtained using an interviewer-administered questionnaire. Questions included in the socio-demographic questionnaire were based on previous studies conducted at Tshepang Clinic (Mapetla, 2007; Engelbrecht, 2010; Meyer et al., 2012), as well as with consideration of the literature (Belak Kovačević et al., 2006; Hasanah et al., 2010). Adherence measures for this study were identified based on adherence measures reported in the literature and those used in previous studies conducted at Tshepang Clinic (Chesney et al., 2000; Mapetla, 2007; Amico et al., 2009; Wilson et al., 2009; Berg et al., 2010; Engelbrecht, 2010; Meyer et al., 2012). Recall on
adherence to HAART over the past 30 days was determined using a self-reported descriptive rating scale with six response options: excellent, very good, good, fair, poor, and very poor. This particular rating scale was used to measure adherence as previous research using cognitive testing indicated that respondents felt more comfortable and confident with words (adjectives and adverbs) compared to numbers. Cognitive estimation of adherence has also matched better with words than with numbers (Wilson et al., 2014; Phillips et al., 2017). Numeric values were assigned to patient-reported adherence ratings based on previous studies conducted at the study sites and published studies on adherence (Mapetla, 2007; Lu et al., 2008; Engelbrecht, 2010; Buscher et al., 2011; Vagiri et al., 2014). This was also supported by our previous study comparing patient-reported adherence ratings with assigned numeric values, which proved ideal in a cross-sectional study conducted with 110 PLWHA at one of the study sites (Tshepang HAART Clinic) (Vagiri et al., 2014). The cognitive process of adherence estimation matched better with the words, and assigned numeric values correlated with patient-reported adherence ratings, which supported the use of the rating scale as a self-report adherence measure in a resource-limited setting (Vagiri et al., 2014).

The data collection instruments were available in English and in Setswana, a local language predominantly spoken in the area where the study was conducted. Forward and back translation of the instruments was performed by two bi-lingual health professionals to provide cross-cultural equivalence. The questionnaires were pilot-tested for feasibility and administered to a sample of 110 PLWHA in an initial cross-sectional study previously conducted at one of the study sites (Tshepang HAART Clinic) (Vagiri et al., 2014). Based on the results of the pilot test, only the adherence questions were amended prior to the commencement of this longitudinal study.

Both the HRQoL and the self-reported adherence rating scale were administered to patients at baseline (Visit 1), and at follow-up visits after 4 months (Visit 2), 8 months (Visit 3) and 12 months (Visit 4). The self-reported adherence rating scale was not administered to patients who were still treatment-naïve at baseline. Socio-demographic and health-related characteristics data were obtained only at baseline. Patients who missed any, or all, of the follow-up study visits over the 12-month study period were excluded from the data analysis as each patient served as their own control.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutions. Permission to conduct the study was obtained from the management of the two study sites and ethical clearance was granted by the Medunsa Campus Research Ethics Committee of the University of Limpopo (MREC/160/2008/PG) and Tshwane Research and Ethics Committee (Project: 2012/16).

Data analysis

Data were captured into a Microsoft Office Excel™ spreadsheet, verified for correctness and cleaned, after which it was exported to Statistical Package for the Social Sciences (SPSS) Version 20.0 for analysis. Socio-demographic data, health-related characteristics data and adherence data were summarised and expressed as frequencies and percentages. The patient-reported adherence ratings were also converted to a percentage as follows: excellent (100%), very good (95%), good (90%), fair (80%), poor (70%), and very poor (<70%) in line with previous studies (Mapetla, 2007; Lu et al., 2008; Engelbrecht, 2010; Buscher et al., 2011; Vagiri et al., 2014). Optimal adherence was set at ≥95% in this study (Turner, 2002; WHO, 2006). Patients with adherence reported as ‘very good’ and ‘excellent’ on the rating scale were classified as adherent (≥95%) and those with adherence ratings of ‘good’, ‘fair’, ‘poor’ and ‘very poor’ were classified as non-adherent (<95%) (Feldman et al., 2013).

All HRQoL domain scores, ranging from one (low or negative perception) to five (high or positive perception), were multiplied by four to enable the scores range from four to 20 (All scores are multiplied by 4 so as to be directly comparable with scores derived from the WHQOL-100). The mean HRQoL domain scores were then averaged to obtain an overall HRQoL score.

An interrupted time-series analysis was conducted to identify the association between adherence and mean HRQoL for the actual duration a patient had been on HAART (Velicer and Fava, 2003). The adherence and HRQoL responses of all patients for the four study visits were pooled to obtain a combined sample (n=1631, excluding 93 treatment-naive patients). All scores were regrouped into 4-monthly intervals, according to the patient’s exact duration on HAART (ranging from 1 to 120 months). Overall mean HRQoL was compared for patients classified as adherent (≥95%) and non-adherent (<95%) for each time interval, using an independent sample t-test, with statistical significance set at p≤0.05. Cohen’s d test was employed to measure appropriate effect size of mean HRQoL scores between adherent and non-adherent patients.

RESULTS

Removing patients who missed any, or all, of the follow-up study visits over the 12-month study period resulted in a 23.6% (n=132) drop-out rate leaving a final sample size of 431 patients.

The majority of the participants were females (76.1%), completed secondary education (74.2%), lived in a family (87.9%), did not consider themselves ill (88.2%) and attended associations supporting HIV and AIDS (81.9%). More than half of the subjects were middle-aged (62.2%), Single (68.7%), unemployed (56.1%), asymptomatic (60.3%) and reported good health (54.0%). Just over a third of the patients did not have any income (36.4%) and 27.8% reported to be living with other HIV and AIDS patients. The mean age of the sample at baseline was 38.5 years (SD: 8.45) (Table 1).

From Table 2, it is evident that more than three-quarters (76.2%) of patients reported being highly adherent (≥95%) to HAART.

A gradual increase in the proportion of adherent (≥95%) patients was observed over time, from Visit 1 (69.5%) to Visit 4 (81.6%) after 12 months (Figure 1). Based on the self-reported adherence rating scale, all patient groups who reported ≥95% adherence, reported higher overall mean HRQoL compared to those <95% adherent, except for patients newly initiated on HAART (1-4 months) and those 41-44 months on HAART (Figure 2). Relatively low and very similar overall HRQoL was reported by adherent and non-adherent patients within the first 4 months of HAART (15.93 and 15.97
Table 1. Socio-demographic and health status characteristics of the study sample at baseline (n=431).

| Socio-demographic and health status characteristics | Frequency (%) |
|-----------------------------------------------------|---------------|
| Gender                                              |               |
| Male                                                | 103 (23.9)    |
| Female                                              | 328 (76.1)    |
| ≥18 - <31                                           | 76 (17.6)     |
| ≥31 - <46                                           | 268 (62.2)    |
| ≥46                                                 | 87 (20.2)     |
| Clinical status                                     |               |
| Asymptomatic                                        | 260 (60.3)    |
| Symptomatic/AIDS                                    | 171 (39.7)    |
| Education                                           |               |
| Primary (Grade 0 – 7)                               | 78 (18.1)     |
| Secondary (Grade 8 – 12)                            | 320 (74.2)    |
| Tertiary                                            | 33 (7.7)      |
| Employment                                          |               |
| Unemployed                                          | 242 (56.1)    |
| Employed                                            | 189 (43.9)    |
| Marital status                                      |               |
| Single                                              | 296 (68.7)    |
| Married                                             | 87 (20.2)     |
| Divorced/Separated/Widowed                          | 48 (11.1)     |
| None                                                | 157 (36.4)    |
| R1 - R2000                                          | 187 (43.4)    |
| R2001 - R5000                                       | 63 (14.6)     |
| More than R5000                                     | 24 (5.6)      |
| Income (in ZAR)                                     |               |
| Good                                                | 362 (84.0)    |
| Neither poor nor good                               | 59 (13.7)     |
| Poor                                                | 10 (2.3)      |
| Consider oneself as ill                             |               |
| Yes                                                 | 51 (11.8)     |
| No                                                  | 380 (88.2)    |

respectively). This could potentially be explained by patients’ clinical HIV status at the start of HAART. Although the overall mean HRQoL for adherent (≥95%) patients was lower than <95% adherent patients in the group 41-44 months on ART, this difference was not statistically significant (p=0.433) (Table 3).

Overall, a statistically significant difference in the mean HRQoL scores of HAART adherent (≥95%) and non-adherent (<95%) patients was observed amongst patients on HAART for the periods 9-28 months, 49-64 months and 81-120 months on treatment (Table 3; Figure 2). The significant differences in mean HRQoL scores between adherent and non-adherent patients was further confirmed by Cohen’s d test, with effect sizes ranging from medium to large (Table 3).

DISCUSSION

The high percentage of women in our study confirms other studies showing higher rates of HIV among women in sub-Saharan Africa compared with men, which is different to the characteristics of patients with HIV in high income countries (Gaida et al., 2016; Kalemeera et al., 2016).

Encouragingly, three quarters of the patients (76.3%) in this study rated their adherence as “excellent” or “very good” on the descriptive patient-reported adherence rating scale; while very few patients (0.5%) rated their adherence as “poor” or “very poor”. Although excellent adherence of ≥95% is required for HAART, a contributing factor to the appreciable number of patients in this study reporting good adherence could be the introduction of a fixed-dose combination (FDC) containing tenofovir, emtricitabine and efavirenz as a first-line regimen during 2013 by the National Department of Health (NDoH) in South Africa. Fixed-dose combinations are known to reduce pill burden, are convenient to take, and evidently promote adherence.
Table 2. Levels of adherence (n=1629).

| Adherence rating (%) | No. (%)a |
|----------------------|----------|
| Poor (70%)           | 8 (0.5)b |
| Fair (80%)           | 31 (1.9) |
| Good (90%)           | 347 (21.3)|
| Very Good (95%)      | 804 (49.4)|
| Excellent (100%)     | 439 (26.9)|

a93 patients were treatment-naive at Visit 1 (baseline), therefore could not rate their adherence; bTwo of the 8 patients reported their adherence as very poor (<70%).

(Farrel et al., 2013; Feldman et al., 2013; Vrijens et al., 2017). This though needs to be explored further before any definitive statements can be made especially as some of these patients will have co-morbidities increasing their pill burden. In our study, chronic co-morbidities and co-infections were not recorded, yet their treatment may have affected patients’ adherence to HAART.

An improvement in HRQoL over time has been elucidated in a number of longitudinal studies; however, the results varied across different research settings. Mannheimer et al. (2005) reported a significant association between adherence and HRQoL in a 12-month prospective, longitudinal study conducted in the USA with 1050 HIV treatment-experienced patients. HRQoL was measured using the SF-12 Health Survey instrument and was administered at baseline, one, four, eight and 12 months respectively. The results described a significant improvement of HRQoL at the first, fourth and twelfth months. Participants who reported 100% adherence to HAART reported significantly higher HRQoL at 12 months compared to those with poorer adherence. As a result, this study also provided evidence that HAART, if taken as prescribed, has a positive effect on QoL similar to our findings (Mannheimer et al., 2008).

Another longitudinal study conducted in Brazil with treatment naïve patients included one baseline interview and three follow-up interviews at the first, fourth and seventh month thereafter. The baseline interview assessed socio-demographic, treatment-related and behavioural characteristics, while follow-up interviews evaluated adherence and HRQoL (assessed using WHOQOL-BREF). The results demonstrated a significant improvement in QoL after four months on HAART. Two-thirds (66.4%) of the patients reported good or very good QoL suggesting an improvement of HRQoL after initiating treatment (Campos et al., 2009). This study supports our study finding that better adherence results in increased QoL.

In our study, patients who reported ≥95% adherence reported better HRQoL compared to patients who reported...
Table 3. Comparison of mean HRQoL scores between adherent (≥95%) and non-adherent (<95%) patients and their effect sizes.

| Patient group | Adherence rate category | n   | Mean HRQoL (SD) | T   | p*  | D  |
|---------------|------------------------|-----|----------------|-----|-----|----|
| 1-4 months    | Adherent (≥95%)        | 38  | 15.93 (0.65)    | -0.3| 0.792| 0.06|
|               | Non-adherent (<95%)   | 58  | 15.97 (0.68)    |     |      |    |
| 5-8 months    | Adherent (≥95%)        | 54  | 16.09 (0.67)    | 0.5 | 0.594| 0.09|
|               | Non-adherent (<95%)   | 87  | 16.03 (0.66)    |     |      |    |
| 9-12 months   | Adherent (≥95%)        | 66  | 16.23 (0.91)    | 2.1 | 0.033| 0.33|
|               | Non-adherent (<95%)   | 102 | 15.94 (0.85)    |     |      |    |
| 13-16 months  | Adherent (≥95%)        | 46  | 16.46 (1.11)    | 2.7 | 0.007| 0.53|
|               | Non-adherent (<95%)   | 66  | 15.90 (1.01)    |     |      |    |
| 17-20 months  | Adherent (≥95%)        | 41  | 16.52 (1.21)    | 3.1 | 0.003| 0.61|
|               | Non-adherent (<95%)   | 62  | 15.82 (1.05)    |     |      |    |
| 21-24 months  | Adherent (≥95%)        | 39  | 16.52 (1.25)    | 3.2 | 0.002| 0.67|
|               | Non-adherent (<95%)   | 55  | 15.72 (1.14)    |     |      |    |
| 25-28 months  | Adherent (≥95%)        | 42  | 16.51 (1.06)    | 2.5 | 0.012| 0.51|
|               | Non-adherent (<95%)   | 65  | 15.95 (1.12)    |     |      |    |
| 29-32 months  | Adherent (≥95%)        | 38  | 16.35 (1.43)    | 1.4 | 0.162| 0.27|
|               | Non-adherent (<95%)   | 68  | 16.00 (1.12)    |     |      |    |
| 33-36 months  | Adherent (≥95%)        | 43  | 16.26 (1.41)    | 0.7 | 0.495| 0.13|
|               | Non-adherent (<95%)   | 63  | 16.10 (1.09)    |     |      |    |
| 37-40 months  | Adherent (≥95%)        | 39  | 16.29 (1.48)    | 0.6 | 0.575| 0.12|
|               | Non-adherent (<95%)   | 52  | 16.13 (1.19)    |     |      |    |
| 41-44 months  | Adherent (≥95%)        | 27  | 15.78 (1.92)    | -0.8| 0.433| 0.19|
|               | Non-adherent (<95%)   | 34  | 16.08 (1.03)    |     |      |    |
| 45-48 months  | Adherent (≥95%)        | 26  | 16.33 (1.64)    | 1.2 | 0.231| 0.33|
|               | Non-adherent (<95%)   | 26  | 15.87 (1.06)    |     |      |    |
| 49-52 months  | Adherent (≥95%)        | 17  | 16.56 (1.88)    | 2.1 | 0.041| 0.65|
|               | Non-adherent (<95%)   | 23  | 15.57 (1.06)    |     |      |    |
| 53-56 months  | Adherent (≥95%)        | 20  | 16.59 (1.92)    | 2.2 | 0.033| 0.67|
|               | Non-adherent (<95%)   | 22  | 15.53 (1.13)    |     |      |    |
| 57-60 months  | Adherent (≥95%)        | 19  | 17.04 (1.25)    | 4.0 | 0.000| 1.25|
|               | Non-adherent (<95%)   | 22  | 15.44 (1.30)    |     |      |    |
| 61-64 months  | Adherent (≥95%)        | 13  | 16.98 (1.28)    | 2.9 | 0.008| 1.07|
|               | Non-adherent (<95%)   | 16  | 15.52 (1.44)    |     |      |    |
| 65-68 months  | Adherent (≥95%)        | 13  | 16.32 (1.44)    | 1.3 | 0.205| 0.48|
|               | Non-adherent (<95%)   | 16  | 15.63 (1.42)    |     |      |    |
| 69-72 months  | Adherent (≥95%)        | 11  | 16.22 (1.06)    | 1.4 | 0.175| 0.53|
|               | Non-adherent (<95%)   | 20  | 15.63 (1.17)    |     |      |    |
| 73-76 months  | Adherent (≥95%)        | 15  | 15.98 (1.43)    | 0.9 | 0.396| 0.32|
|               | Non-adherent (<95%)   | 14  | 15.58 (1.03)    |     |      |    |
| 77-80 months  | Adherent (≥95%)        | 15  | 15.94 (1.44)    | 1.1 | 0.302| 0.35|
|               | Non-adherent (<95%)   | 20  | 15.46 (1.27)    |     |      |    |
| 81-120 months | Adherent (≥95%)        | 43  | 16.48 (1.23)    | 4.2 | 0.000| 0.79|
|               | Non-adherent (<95%)   | 75  | 15.58 (1.04)    |     |      |    |
| All patient groups | Adherent (≥95%)   | 704 | 16.31 (1.26)    | 7.9 | 0.000| 0.38|
|               | Non-adherent (<95%)   | 1020| 15.87 (1.03)    |     |      |    |

*p<0.05, Independent sample t-test; SD: Standard deviation; d: Cohen’s d for Independent sample t-test.

<95% over a period of 12 months (Table 2). We know HAART potentially improves HRQoL and contributes to enhanced treatment via better adherence to HAART (Smit et al., 2015; Mataranyika et al., 2018). This finding was supported by a multi-site cohort study conducted in the USA where PLWHA who had a
Figure 2. Time series analysis comparing level of adherence and mean HRQoL over time (n=1631).

meaningful, comfortable life, who were well cared for, and who used their time wisely, reported better adherence to their treatment (Liu et al., 2013). In addition, better adherence is known to result in greater suppression of the virus and results in increased HRQoL (Lyimo et al., 2012). This association between adherence to HAART and HRQoL is further confirmed by the results of our time-series analysis (Figure 2). Irrespective of the time on HAART, it was revealed that adherent patients (≥95%) consistently reported better HRQoL compared to the non-adherent patients.

It is recognise though that consideration of the role of social capital in adherence to HAART needs to be better understood in South Africa building on previous research (Binagwaho and Ratnayake, 2009; Jakovljevic and Milovanovic, 2015), and this will be investigated further in future.
studies. It is also known that this study had some limitations. Firstly, it was conducted at only two treatment centres, hence the results cannot be generalised to the entire country, although we believe patients attending these two clinics are typical of those attending public health clinics throughout South Africa. Secondly, the drop-out rate over the 12-month follow-up period, as well as recall and social desirability bias due to patient self-report on adherence and HRQoL, could have inflated some of the data. Thirdly, numeric values were assigned to patient-reported adherence ratings, which may have influenced levels of adherence presented; although, this did not have an effect on actual categorisation of adherent (≥95%) and non-adherent patients (<95%) as optimal adherence for this study was set at ≥95% according to WHO adherence guidelines (WHO, 2006). However, despite these limitations, we believe our findings are robust in view of the methodology we employed.

Conclusion

Encouragingly, there were high adherence rates to HAART in this study, with this study establishing a significant relationship between HRQoL and adherence to HAART over time. Adherent patients consistently reported better HRQoL compared to the non-adherers irrespective of the period of time on HAART, underlining the importance of adherence in improving HRQoL in patients with HIV. Adherence to HAART is complex and it is a dynamic and biosocial process influenced by diverse factors influencing HRQoL in a positive or negative manner. As HAART is a lifelong treatment, assessing patients' adherence behaviour and improving adherence will maximise the benefits of HAART and enhance patients' HRQoL. This builds on the South African government's initiatives to improve adherence to HAART. Whilst HAART increases the lifespan of PLWHA, their HRQoL remains a concern. This can be improved with improved adherence. Understanding the social consequences of this disease, and making appropriate clinical interventions, can also improve HRQoL, and we will be exploring this further in future research.

CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.

ACKNOWLEDGEMENTS

The authors appreciate the patients who participated in this study. Sincere gratitude also go to Prof Herman Schoeni for the statistical analysis of the data, Wellington Maluleke, Wilhelmina Makhubele, Sannie Molewa and Shiela Masilo for the data collection. The School of Pharmacy, Sefako Makgatho Health Sciences University is acknowledged for logistical support and contribution. The authors would like to express their sincere gratitude to the South African Medical Research Council (SAMRC) for funding this study.

REFERENCES

Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, Mussini C, Bai F, Orofino G, Sighinolfi L, Gori A, Suter F, Maggioni F (2010). One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Preference and Adherence 13 (4):115-125.

Alhoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, Rimland D, Rodriguez-Barradas MC, Dubrow R, Park LS, Sherrard M, M. Shier J, Gange SJ, Gebo KA, Justice AC, Veterans Aging Cohort Study (VACS) (2014). Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected vs uninfected adults. Clinical Infectious Diseases 60:627-638. doi: 10.1093/cid/ciu869.

Alhoff KN, Smit M, Reiss P, Justice AC (2016). HIV and ageing: improving quantity and quality of life. Current Opinion in HIV and AIDS 11(5):527-536. doi: 10.1097/COH.0000000000000305.

Amico KR, Simoni J, Wilson I, Malow RM, Devieux J, Deschamps A (2009). Monitoring Patient Adherence: Recommendations from and for Practice. Proceedings of the 4th Annual International Conference on HIV Treatment Adherence; 2009 April 6. Miami, USA.

AVERT (2017). Available at: https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/overview

Balderson BH, Grothaus L, Harrison RG, McCoy K, Mahoney C, Catz S (2013). Chronic illness burden and quality of life in an aging HIV population. AIDS care 25(4):451-8. doi: 10.1080/09540121.2012.712669.

Bakiono F, Ouédraogo L, Sanou M Samadoulouguo S, Guiuemedé PW, Kirakoya-Samadoulouguo F, Robert A (2014). Quality of life in people living with HIV: a cross-sectional study in Ouagadougou, Burkina Faso. Springerplus 3(372), doi:10.1186/2193-1801-3-372.

Belak Kovačević S, Vurusić T, Duvancić K, Macek M (2006). Quality of life in people living with HIV: a cross-sectional study in Ouagadougou, Burkina Faso. Springerplus 3(372), doi:10.1186/2193-1801-3-372.

Binaqwahao A, Ratnayeke N (2009). The role of social capital in successful adherence to antiretroviral therapy in Africa. PLoS medicine 27:5(1):e18. doi: 10.1371/journal.pmed.1000018.

Bello SI, Bello IK (2013). Quality of life of HIV/AIDS patients in a secondary health care facility, Ilorin, Nigeria. Proceedings (Baylor University, Medical Center) 26(2):116-119.

Berg KM, Wilson IB, Li X, Aronstein JH (2010). Comparison of antiretroviral adherence questions. AIDS and Behavior 16(2):461-468. doi: 10.1007/s10461-010-9864-z.

Buscher A, Hartman C, Kallen MA, Giordano TP (2011). Validity of self-report measures in assessing antiretroviral adherence of newly diagnosed, HAART-naive, HIV patients. HIV clinical trials 12(5):244-254. doi: 10.1310/htc1205-244.
Campos LN, César CC, Guimarães MD (2009). Quality of life among HIV-infected patients in Brazil after initiation of treatment. Clinics (Sao Paulo) 64(9):867-875. doi: 10.1590/S1807-5932900000007.

Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 12(3):255-266.

Cohen CJ, Meyers JL, Davis KL (2013). Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicated population with HIV. BMJ Open 3:e003028. doi:10.1136/bmjopen-2013-003028.

Cois A, Day C (2015). Obesity trends and risk factors in the South African adult population. BMC obesity. 2:42. https://doi.org/10.1186/s40608-015-0072-2

Deeks SG, Phillips AN (2009). HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ (Clinical research ed.) 338:a3172. doi: 10.1136/bmj.a3172.

Degroote S, Vogelaers D, Vandijck DM (2014). What determines health-related quality of life among people living with HIV: an updated review of the literature. Archives of Public Health 72(1):40. doi:10.1186/2049-2528-72-40.

Engelberg CJ, Kalemeera F, Mbango C, Mubita M, Naikaku E, Gaida R, Godman B (2018). The Impact of an Electronic Medication Monitoring System on the adherence of patients to antiretroviral medication at Tshepang ARV Clinic, Dr George Mukhari Hospital [dissertation]. Pretoria: University of Limpopo, Medunsa Campus.

Etenyi JO, Okalebo FA, Oluka M, Sinei KA, Osanjo GO, Kurdi A, Meyer JC, Godman B, Opana S (2018). Comparison of zidovudine and tenofovir based regimens with regard to health-related quality of life and prevalence of symptoms in HIV patients in a Kenyan referral hospital. Frontiers in Pharmacology 9:984. doi: 10.3389/fphar.2018.00984.

Farrell B, French Merkley V, Ingar N (2013). Reducing pill burden and helping with medication awareness to improve adherence. Canadian Pharmacists Journal 146(5):262-269. doi:10.1177/171516351300208.

Fatiregun A, Mofolorunsho KC, Osagbemi KG (2009). Quality of life of people living with HIV/AIDS in Kogi State, Nigeria. Benin Journal of Postgraduate Medicine 11(1):21-27. http://dx.doi.org/10.4314/bjpm.v11i1.48823

Fieldman BJ, Fredericksen RJ, Crane PK, Safren SA, Mugavero MJ, Willig JH, Simoni JM, Wilson IB, Saag MS, Kitahata MM, Crane HM (2013). Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV: AIDS and Behavioral Sciences 17(1):307-318. doi: 10.1080/14787210.2016.1202759.

Gaida R, Truter I, Grobler C, Kotze T, Godman B (2016). A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications. Expert Review of Anti-Infective Therapy 14(4):377-388. doi: 10.1586/14787210.2016.1157469.

Geocce L, Mucci S, De Marco MA, Nogueira-Martins LA, Citero Vde A (2010). Quality of life and adherence to HAART in HIV-infected patients. Revista de Saúde Pública 44(4):743-749. http://dx.doi.org/10.1590/S0034-89102010000400019

Grossman HA, Sullivan PS, Wu AW (2003). Quality of life and HIV: current assessment tools and future directions for clinical practice. The AIDS Reader 13(12):583-590, 595-597.

Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Paella F (2011). Premature age-related comorbidities among HIV-infected persons compared with the general population. Clinical Infectious Diseases 53:1120-1126. doi: 10.1093/cid/cir627.

Hasanah CI, Zalha AR, Mahiran M (2010). Factors influencing the quality of life in patients with HIV in Malaysia. Quality of Life Research 20(1):91-100. doi:10.1007/s11136-010-9729-y.

Hsiung PC, Fang CT, Wu CH, Sheng WH, Chen SC, Wang JD, Yao G (2017). Validation of the WHOQOL-HIV-BREF among HIV-infected patients in Taiwan. AIDS Care 23(8):1035-1042. doi: 10.1080/09540121.2010.543881.

Imam MH, Karim MR, Ferdous C, Akhter S (2011). Health related quality of life among the people living with HIV. Bangladesh Medical Research Council Bulletin 37(1):1-6.

Jakovljevic MB, Milovanovic O (2015). Growing burden of noncommunicable diseases in the emerging health markets: the case of BRICS. Frontiers in Public Health 3:65. doi: 10.3389/fpubh.2015.00065.

Kadam P, Bhalerao S (2010). Sample size calculation. International Journal of Ayurveda Research 1(1):55-7. doi: 10.4103/0974-7788.59946.

Kalemeera F, Mbango C, Mubita M, Naikaku E, Gaida R, Godman B (2016). Effect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia. Expert Review of Anti-Infective Therapy 14(8):777-83. doi: 10.1087/14787210.2016.1202759.

Kalemeera F, Cockeren M, Mubita M, Kibuule D, Naikaku E, Massele A, Godman B (2017). The Potential Effect of Using the Cockcroft-Gault Method on Tenofovir-Associated Renal Impairment Reports and on Clinical Decisions Regarding Tenofovir Use in Individual Patients: Implications for the Future. Journal of Infectious Diseases and Preventive Medicine 5(3):170. doi: 10.4172/2329-8731.1000170.

Liu H, Yu Y, Lin X, Shi J, Chen S (2013). Associations between perceived HIV stigma and quality of life at the dyadic level: the actor-partner interdependence model. PLoS One, 8(2). doi: 10.1371/journal.pone.0055690.

Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, Wilson IB (2008). Optimal recall period and response task for self-reported HIV medication adherence. AIDS and Behavior 12(1):86-94. doi: 10.1007/s10461-007-9261-4.

Lyimo RA, de Bruin M, van den Boogaard J, Hoppers JV, van der Ven A, Mushii D (2012). Determinants of antiretroviral therapy adherence in northern Tanzania: a comprehensive picture from the patient perspective. BMC Public Health 12(716). https://doi.org/10.1186/1471-2458-12-716

Mannheimer SB, Matts J, Telzak E, Chesney M, Child C, Wu AW, Friedland G, Terry Beirn Community Programs for Clinical Research on AIDS (2005). Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 17(1):10-22.

Mannheimer SB, Wold N, Gardner EM, Telzak EE, Hupper Hullisiek K, Chesney M, Wu AW, MacArthur RD, Matts J, Friedland G, Terry Beirn Community Programs for Clinical Research on AIDS (2008). Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals. Clinical Infectious Diseases 46(6):941-945. doi: 10.1086/528859.

Mapella K (2007). Quantification of Antiretroviral Regimen adherence in selected treatment centres in South Africa [dissertation]. Pretoria: University of Limpopo, Medunsa Campus.

Mataranyaka PA, Kibuule D, Kalemeera F, Kaura H, Godman B, Rennie TW (2017). Liver enzyme elevations in a cohort of HIV/AIDS patients on first-line antiretroviral therapy in Namibia: findings and implications. Alexandria Journal of Medicine 54:49-56. doi:10.1016/j.ajme.2017.03.002. Meemon N, Paek SC, Tenchadi D, Wan TT (2016). Application of the WHOQOL-HIV-BREF Questionnaire in HIV-Infected Thai Patients: Reliability and Validity of the Instrument. The Journal of the Association of Nurses in AIDS Care 27(5):698-708. doi:10.1016/j.jana.2016.04.007.

Meyer JC, Summers B, Lentoanea PP, Mokova MV, Nyingwa J, Teftu SM (2012). Is a simple self-rating or visual analogue scale more accurate than prescription refill data, as an indicator of non-adherence in a resource-limited setting in South Africa? Proceedings of the 7th International Conference on HIV Treatment and Prevention Adherence; 2012 June 3-5; Miami, USA.

Meyer JC, Schellack N, Stokes J, Lancaster R, Zeeman H, Dety F, Godman B, Steel G (2017). Ongoing Initiatives to Improve the Quality and Efficiency of Medicine Use within the Public Healthcare Sector in South Africa: A Review of selected treatment centres in South Africa [dissertation]. Pretoria: University of Limpopo, Medunsa Campus.

Mghamba FW, Minzi OM, Massawe A, Sasi P (2013). Adherence to
antiretroviral therapy among HIV infected children measured by caretaker report, medication return, and drug level in Dar Es Salaam, Tanzania. BMC Pediatrics 13:95. doi:10.1186/1471-2431-13-95.

Moorthi M (2014). Closer to zero: Reflections on ten years of ART rollout. South African Journal of HIV Medicine 15(1):9. doi:10.4102/hivmed.v15i1.31.

Ncama BP, McInerney PA, Bhengu BR, Corless IB, Wanlant DJ, Nicholas PK, McGibbon CA, Davis SM (2008). Social support and medication adherence in HIV disease in KwaZulu-Natal, South Africa. International Journal of Nursing Studies 45(12):1757-1763. doi:10.1016/j.ijnurstu.2008.06.006.

Noordzij M, Tripepi G, Dekker FW, Zoccali C, Tanck MW, Geerlings S, Saddki N, Noor MM, Norbanee TH, Rusli MA, Norzila Z, Zaharah S, de Wolf F, Hallett TB, ATHENA observational cohort (2015). Future challenges for clinical care of an ageing population infected with HIV: a modelling study. The Lancet Infectious Diseases 15(7):810-818. doi:10.1016/S1473-3099(15)00566-0.

Statistics South Africa (2018). Mid-year population estimates. Available at: http://www.statssa.gov.za/publications/P0302/P03022018.pdf.

Tesfaye M, Olsen MF, Medhin G, Friis H, Hanlon C, Holm L (2016). Adaptation and validation of the short version WHOQOL-HIV in Ethiopia. International Journal of Mental Health Systems 10:29. http://dx.doi.org/10.1186/s12963-016-0062-x.

Turner BJ (2002). Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. The Journal of Infectious Diseases 185(2):S143-151.

Vagiri MV, Meyer JC, Gous AGS (2014). Satisfaction with aspects of health-related quality of life (HRQoL) amongst HIV positive patients attending a tertiary hospital clinic in South Africa. African Journal for Physical Health Education, Recreation and Dance 1(1):22-31.

Van Tam VL, Larsson M, Pharris A, Diedrichs B, Nguyen HP, Nguyen CT, Ho PD, Marrone G, Thorsen A (2012). Peer support and improvement of quality of life among persons living with HIV on antiretroviral treatment: a randomised controlled trial from north-eastern Vietnam. Health and Quality of Life Outcomes 10(53).

Vagiri et al.          131

Diseases 59:1787-1797. doi: 10.1093/cid/ciu701.

Silva AC de O e, Reis RK, Nogueira JA, Gir E (2014). Quality of life, clinical characteristics and treatment adherence of people living with HIV/AIDS. Revista da Sociedade Brasileira de Medicina Tropical 47(3):309-314. doi:10.1590/S0037-86822014000300006.

Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, Sighem AV, de Wolf F, Hallett TB, ATHENA observational cohort (2015). Future challenges for clinical care of an ageing population infected with HIV: a modelling study. The Lancet Infectious Diseases 15(7):810-818. doi:10.1016/S1473-3099(15)00566-0.

Statistics South Africa (2018). Mid-year population estimates. Available at: http://www.statssa.gov.za/publications/P0302/P03022018.pdf.

Surur AS, Teni FS, Wale W, Ayalew Y, Tesfaye B (2017). Health related quality of life of HIV/AIDS patients on highly active antiretroviral therapy at a university referral hospital in Ethiopia. BMC Health Services Research 17(1):737. doi:10.1186/s12913-017-2714-161.

Tesfaye A, Gebremariam A, Gebbara M, Abbra H (2015). Gender differences in health related quality of life among people living with HIV on highly active antiretroviral therapy in Mekelle Town, Northern Ethiopia. Biomed Research International Article ID 516369. Available from: doi:10.1155/2015/516369.

Tesfaye M, Olsen MF, Medhin G, Friis H, Hanlon C, Holm L (2016). Adaptation and validation of the short version WHOQOL-HIV in Ethiopia. International Journal of Mental Health Systems 10:29. http://dx.doi.org/10.1186/s12963-016-0062-x.

Turner BJ (2002). Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. The Journal of Infectious Diseases 185(2):S143-151.

Tran BX (2012). Quality of life outcomes of antiretroviral treatment for HIV/AIDS patients in Vietnam. PLoS One 7(7): e41062. doi:10.1371/journal.pone.0041062.

United Nations Programme on HIV and AIDS (UNAIDS) (2016). Global AIDS Update. Available at: http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf.

United Nations Programme on HIV and AIDS (UNAIDS) (2017). UNAIDS Data 2017. Available at: http://www.unaids.org/en/resources/documents/2017/2017_data_book.pdf.

U.S. Department of Health & Human Services (N DoH) (2017). Available at: https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics.

Vagiri MV, Meyer JC, Gous AGS (2014). Satisfaction with aspects of health-related quality of life (HRQoL) amongst HIV positive patients attending a tertiary hospital clinic in South Africa. African Journal for Physical Health Education, Recreation and Dance 1(1):22-31.

Van Tam VL, Larsson M, Pharris A, Diedrichs B, Nguyen HP, Nguyen CT, Ho PD, Marrone G, Thorsen A (2012). Peer support and improvement of quality of life among persons living with HIV on antiretroviral treatment: a randomised controlled trial from north-eastern Vietnam. Health and Quality of Life Outcomes 10(53). doi:10.1186/1477-7525-10-53.

Velicer WF, Fava JL (2003). Time Series Analysis. Research Methods in Psychology. Handbook of Psychology. Schinka JA & Velicer WF (Eds.) Volume 2, New York: John Wiley and Sons.

Venter WD, Ford N, Vitoria M, Stevens W (2017). Diagnosis and monitoring of HIV programmes to support treatment initiation and follow up and improve programme quality. Current opinion in HIV and AIDS 12(2):117-122. doi:10.1097/COH.0000000000000354.

Viviers B, Antoniou S, Burnier M, de la Sierra A, Volpe M (2017). Current Situation of Medication Adherence in Hypertension. Frontiers in Pharmacology 8:100. doi:10.3389/fphar.2017.00100.

Wang Z, Zhou J, He G, Luo Y, Li X, Yang A, Fennie K, Williams AB (2009). Consistent ART adherence is associated with improved quality of Life, CD4 counts, and reduced hospital costs in central China. AIDS Research and Human Retroviruses 25:757-763. doi:10.1016/j.aidsvir.2008.10.033.

Wilson IB, Carter AE, Berg KM (2009). Improving the self-report of HIV
antiretroviral medication adherence: is the glass half full or half empty? Current HIV/AIDS Report 6(4):177-186.
Wilson I.B, Fowler FJ, Cosenza CA, Michaud J, Bentkover J, Rana A, Kogelman L, Rogers WH (2014). Cognitive and Field Testing of a New Set of Medication Adherence Self-Report Items for HIV Care. AIDS and Behavior 18(12):2349–258.
World Health Organization (WHO) (2006). From access to adherence: the challenges of antiretroviral treatment Available at: http://www.who.int/medicines/publications/challenges_arvtreatment15Aug2006.pdf

World Health Organization (WHO) (2014). HIV/AIDS prevalence in sub-Saharan Africa Data by sex and residence. Available at: http://apps.who.int/gho/data/node.main.n247?lang=en
World Health Organization (WHO) (2018). Global Health Observatory (GHO): HIV/AIDS. Available at: http://www.who.int/gho/hiv/en/
